ROCKVILLE, Md., Dec. 17, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, today announced the closing of a previously announced underwritten public offering of 13,225,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 1,725,000 shares, offered at a price to the public of $1.00 per share. The gross proceeds to the Company were $13,225,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.
Aegis Capital Corp. acted as sole book-running manager of the offering.
This offering was made pursuant to a shelf registration statement that the Company previously filed with the Securities and Exchange Commission (SEC) and which became effective on July 16, 2013. Electronic copies of the preliminary prospectus supplement and, the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from the SEC’s website at http://www.sec.gov or from Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019 or via telephone at 212-813-1010 or email: email@example.com.
This press release is neither an offer to sell nor a solicitation of an offer to buy any of the Company’s securities. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
Further information regarding the offering is contained in the Company’s Current Report on Form 8-K filed with the SEC and which may be accessed at www.sec.gov.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of product candidates for serious infectious and other diseases. Synthetic Biologics is developing oral treatments targeting archaea, a non-bacterial intestinal form of life increasingly associated with chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C. diff infection, a series of monoclonal antibodies (mAbs) for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of IBS. In addition, the Company is developing an oral estriol drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS (with results of an ongoing 164 subject, 15 center, two-year, double blind, placebo controlled, Phase II relapsing-remitting MS clinical trial expected to be announced during the first half of 2014). For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to this offering and the successful execution of the Company’s business strategy, including with respect to the Company’s research and development and clinical evaluation efforts. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 16, 2013 and in the Company’s periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
SOURCE Synthetic Biologics, Inc.
Released December 17, 2013